NCT00539162 is a NA clinical trial of Questionnaire in Ovarian Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00539162?

NCT00539162 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00539162?

Interventions in NCT00539162: Questionnaire.

What condition does NCT00539162 study?

NCT00539162 studies Ovarian Cancer.

Is NCT00539162 still recruiting?

NCT00539162 is currently recruiting now. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT00539162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Recruiting now NA Last updated 16 April 2026

What this trial tests

NA trial testing Questionnaire in Ovarian Cancer in 8,000 participants. Currently enrolling.

Timeline

2 July 2001

Primary endpoint
30 November 2028

30 November 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	8,000
Start date	2 July 2001
Primary completion	30 November 2028
Estimated completion	30 November 2028
Sites	11 locations across United States

Drugs / interventions tested

Questionnaire

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 50 to 74, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
Lu KH, Skates S, Hernandez MA, Bedi D, et al · · 2013 · cited 90× · PMID 23983047 · DOI 10.1002/cncr.28183
Early detection biomarkers for ovarian cancer.
Sarojini S, Tamir A, Lim H, Li S, et al · · 2012 · cited 64× · PMID 23319948 · DOI 10.1155/2012/709049
Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.
Singh A, Gupta S, Sachan M. · · 2019 · cited 50× · PMID 31608277 · DOI 10.3389/fcell.2019.00182
Normal Risk Ovarian Screening Study: 21-Year Update.
Han CY, Lu KH, Corrigan G, Perez A, et al · · 2024 · cited 12× · PMID 38194613 · DOI 10.1200/jco.23.00141
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
Young Han C, Bedia JS, Yang WL, Hawley SJ, et al · · 2024 · cited 10× · PMID 38195887 · DOI 10.1038/s41416-023-02560-z
Validation of machine learning-based models to predict and explain the risk of ovarian cancer: a multicentric study on <i>BRCA</i>-mutated patients undergoing risk-reducing salpingo-oophorectomy.
Loizzi V, Comes MC, Arezzo F, Apostol AI, et al · · 2025 · PMID 40303993 · DOI 10.3389/fonc.2025.1574037

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00539162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00539162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing